CA2961894C - Methods for treating brain metastatis using gap junction inhibitors - Google Patents

Methods for treating brain metastatis using gap junction inhibitors Download PDF

Info

Publication number
CA2961894C
CA2961894C CA2961894A CA2961894A CA2961894C CA 2961894 C CA2961894 C CA 2961894C CA 2961894 A CA2961894 A CA 2961894A CA 2961894 A CA2961894 A CA 2961894A CA 2961894 C CA2961894 C CA 2961894C
Authority
CA
Canada
Prior art keywords
cancer
gap junction
inhibitor
subject
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2961894A
Other languages
English (en)
French (fr)
Other versions
CA2961894A1 (en
Inventor
Adrienne BOIRE
Qing Chen
Joan Massague
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CA2961894A1 publication Critical patent/CA2961894A1/en
Application granted granted Critical
Publication of CA2961894C publication Critical patent/CA2961894C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
CA2961894A 2014-09-19 2015-09-18 Methods for treating brain metastatis using gap junction inhibitors Active CA2961894C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052966P 2014-09-19 2014-09-19
US62/052,966 2014-09-19
PCT/US2015/051057 WO2016044790A1 (en) 2014-09-19 2015-09-18 Methods for treating brain metastasis

Publications (2)

Publication Number Publication Date
CA2961894A1 CA2961894A1 (en) 2016-03-24
CA2961894C true CA2961894C (en) 2023-12-12

Family

ID=55533931

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2961894A Active CA2961894C (en) 2014-09-19 2015-09-18 Methods for treating brain metastatis using gap junction inhibitors

Country Status (7)

Country Link
US (3) US10413522B2 (enExample)
EP (2) EP3685832B1 (enExample)
JP (1) JP6898848B2 (enExample)
CN (1) CN107106544B (enExample)
AU (3) AU2015317330B2 (enExample)
CA (1) CA2961894C (enExample)
WO (1) WO2016044790A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106544B (zh) * 2014-09-19 2021-09-24 纪念斯隆-凯特琳癌症中心 用于治疗脑转移瘤的方法
CN107290438B (zh) * 2016-03-31 2020-10-16 深圳翰宇药业股份有限公司 一种多肽有关物质的高效液相色谱分析方法
WO2019014246A1 (en) * 2017-07-10 2019-01-17 Cantley Lewis C TARGETING CHROMOSOMIC INSTABILITY AND SIGNALING OF CYTOSOLIC DNA IN AVAL FOR THE TREATMENT OF CANCER
AU2018314234B2 (en) * 2017-08-11 2024-10-24 Board Of Regents, The University Of Texas System Targeting kinases for the treatment of cancer metastasis
US11717506B2 (en) 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis
WO2021051015A1 (en) * 2019-09-13 2021-03-18 Auckland Uniservices Limited Compositions and methods for rescuing retinal and choroidal structure and function
CN111420025B (zh) * 2020-04-28 2021-06-11 中国药科大学 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用
GB202014831D0 (en) 2020-09-21 2020-11-04 Dc Europa Ltd Disconnection agents
US12306192B2 (en) * 2021-02-08 2025-05-20 Cedars-Sinai Medical Center Method of detecting cognitive impairment
CN114252324B (zh) * 2022-03-02 2022-05-13 中国人民解放军军事科学院军事医学研究院 一种方便使用的多孔脑片孵育装置
WO2024020491A1 (en) * 2022-07-20 2024-01-25 The University Of North Carolina At Chapel Hill Methods of treating cancer of the central nervous system comprising 5-ethynyl-2'-deoxyuridine
WO2025024284A1 (en) * 2023-07-21 2025-01-30 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against pcdh7 for lung cancer therapy
CN117298143A (zh) * 2023-10-11 2023-12-29 广州医科大学附属第一医院（广州呼吸中心） β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411635D0 (en) 1994-06-10 1994-08-03 Smithkline Beecham Plc Novel treatment
JPH10501256A (ja) 1994-06-10 1998-02-03 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｃ−４アミド置換化合物およびその治療剤としての使用
AU740588B2 (en) 1997-11-24 2001-11-08 Scripps Research Institute, The Inhibitors of gap junction communication
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6251931B1 (en) 1998-11-24 2001-06-26 The Scripps Research Institute Inhibitors of gap junction communication
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6770633B1 (en) 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
EP1582219A4 (en) 2002-11-29 2007-11-28 Japan Science & Tech Agency CONNEXIN 26 INHIBITORS AND INHIBITORS OF TUMORMETASTASES
KR20060054405A (ko) * 2003-07-31 2006-05-22 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 암, 암의 발병 또는 암 증상의 치료, 예방 및/또는 개선용조성물 및 방법
ES2766549T3 (es) 2005-02-03 2020-06-12 Coda Therapeutics Ltd Compuestos anticonexina 43 para el tratamiento de heridas crónicas
US7704946B2 (en) 2006-05-05 2010-04-27 Caritas St. Elizabeth's Medical Center Reversible inhibition of pyramidal gap junction activity
CA2710232A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
CA2726878A1 (en) * 2008-06-05 2009-12-10 Minster Research Limited Novel treatments
EP2331093A4 (en) * 2008-08-27 2016-06-01 Univ Columbia COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATMENT PREVENTING DISEASES
FR2935611B1 (fr) * 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20110262442A1 (en) * 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
AU2010325755A1 (en) 2009-12-03 2012-06-21 Proximagen Ltd Treatment of infectious diseases
JP2013512887A (ja) * 2009-12-03 2013-04-18 プロキシマゲン リミテッド 感染症の治療
WO2014129914A1 (en) * 2013-02-22 2014-08-28 Auckland Uniservices Limited Methods of treatment
CA2908154C (en) * 2013-04-29 2023-11-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
EP3057977A4 (en) 2013-10-15 2017-07-26 President and Fellows of Harvard College Methods and compositions for eradicating leukemic cells
CN107106544B (zh) * 2014-09-19 2021-09-24 纪念斯隆-凯特琳癌症中心 用于治疗脑转移瘤的方法

Also Published As

Publication number Publication date
CA2961894A1 (en) 2016-03-24
AU2023219864A1 (en) 2023-09-14
AU2021202257B2 (en) 2023-05-25
JP6898848B2 (ja) 2021-07-07
EP3685832A1 (en) 2020-07-29
US10413522B2 (en) 2019-09-17
AU2021202257A1 (en) 2021-05-06
US20170258758A1 (en) 2017-09-14
AU2015317330A1 (en) 2017-04-13
US11058665B2 (en) 2021-07-13
CN107106544B (zh) 2021-09-24
EP3193865A4 (en) 2018-04-11
JP2017534583A (ja) 2017-11-24
CN107106544A (zh) 2017-08-29
US20220105069A1 (en) 2022-04-07
EP3193865A1 (en) 2017-07-26
WO2016044790A1 (en) 2016-03-24
US12029717B2 (en) 2024-07-09
EP3685832B1 (en) 2023-08-30
NZ730319A (en) 2024-03-22
EP3193865B1 (en) 2019-11-06
US20200085781A1 (en) 2020-03-19
AU2015317330B2 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
AU2021202257B2 (en) Methods for treating brain metastasis
Chen et al. Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer
He et al. circ-SHKBP1 regulates the angiogenesis of U87 glioma-exposed endothelial cells through miR-544a/FOXP1 and miR-379/FOXP2 pathways
Li et al. Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes
Du et al. Targeting the SMO oncogene by miR-326 inhibits glioma biological behaviors and stemness
Rupp et al. IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor–stroma interaction
Cai et al. MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis
Kim et al. Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells
Hirahata et al. PAI‐1, a target gene of miR‐143, regulates invasion and metastasis by upregulating MMP‐13 expression of human osteosarcoma
Wang et al. Hsa_circ_0128846 promotes tumorigenesis of colorectal cancer by sponging hsa‐miR‐1184 and releasing AJUBA and inactivating Hippo/YAP signalling
Wang et al. STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer
Zhan et al. Ovarian cancer stem cells: a new target for cancer therapy
Artibani et al. WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel
Scaravilli et al. Androgen-driven fusion genes and chimeric transcripts in prostate cancer
Hu et al. Inhibition of Pten deficient castration resistant prostate cancer by targeting of the SET-PP2A signaling axis
Tang et al. The role of the AMOP domain in MUC4/Y-promoted tumour angiogenesis and metastasis in pancreatic cancer
Anand et al. MYB sustains hypoxic survival of pancreatic cancer cells by facilitating metabolic reprogramming
Rao et al. OVA66 increases cell growth, invasion and survival via regulation of IGF-1R–MAPK signaling in human cancer cells
US10295530B2 (en) Functional assay for cancer recurrence and malignant potential
Park et al. Endothelial snail regulates capillary branching morphogenesis via vascular endothelial growth factor receptor 3 expression
Tse et al. Activation of Wnt signaling pathway by AF1q enriches stem-like population and enhance mammosphere formation of breast cells
US20150184247A1 (en) Gene expression profiles associated with metastatic breast cancer
Sun et al. circTOP2A functions as a ceRNA to promote glioma progression by upregulating RPN2
Shigeishi et al. PGE2 targets squamous cell carcinoma cell with the activated epidermal growth factor receptor family for survival against 5-fluorouracil through NR4A2 induction
Liu et al. Neural cell adhesion molecule potentiates the growth of murine melanoma via β-catenin signaling by association with fibroblast growth factor receptor and glycogen synthase kinase-3β

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200910

EEER Examination request

Effective date: 20200910

EEER Examination request

Effective date: 20200910

EEER Examination request

Effective date: 20200910

EEER Examination request

Effective date: 20200910

EEER Examination request

Effective date: 20200910

EEER Examination request

Effective date: 20200910

EEER Examination request

Effective date: 20200910

EEER Examination request

Effective date: 20200910

EEER Examination request

Effective date: 20200910